Summary
Global Markets Direct’s, ‘Malignant Pleural Mesothelioma - Pipeline Review, H1 2016’, provides an overview of the Malignant Pleural Mesothelioma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malignant Pleural Mesothelioma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma
- The report reviews pipeline therapeutics for Malignant Pleural Mesothelioma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Malignant Pleural Mesothelioma therapeutics and enlists all their major and minor projects
- The report assesses Malignant Pleural Mesothelioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Malignant Pleural Mesothelioma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Malignant Pleural Mesothelioma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Aduro BioTech, Inc.
Advantagene, Inc.
Amphera BV
AnGes MG, Inc.
ArQule, Inc.
Bayer AG
Biogen, Inc.
Bionomics Limited
Biotecnol, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
CanBas Co., Ltd.
Concordia Healthcare Corp.
Eli Lilly and Company
EnGeneIC Ltd
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genelux Corporation
GlaxoSmithKline Plc
Juno Therapeutics Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Morphotek, Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Oxford BioMedica Plc
Pfizer Inc.
Pharma Mar, S.A.
Polaris Pharmaceuticals, Inc.
Sellas Inc.
Synta Pharmaceuticals Corp.
VasGene Therapeutics, Inc.
Verastem, Inc.
Virttu Biologics Limited
Vyriad
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Malignant Pleural Mesothelioma Overview 8
Therapeutics Development 9
Pipeline Products for Malignant Pleural Mesothelioma - Overview 9
Pipeline Products for Malignant Pleural Mesothelioma - Comparative Analysis 10
Malignant Pleural Mesothelioma - Therapeutics under Development by Companies 11
Malignant Pleural Mesothelioma - Therapeutics under Investigation by Universities/Institutes 13
Malignant Pleural Mesothelioma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Malignant Pleural Mesothelioma - Products under Development by Companies 17
Malignant Pleural Mesothelioma - Products under Investigation by Universities/Institutes 20
Malignant Pleural Mesothelioma - Companies Involved in Therapeutics Development 21
Aduro BioTech, Inc. 21
Advantagene, Inc. 22
Amphera BV 23
AnGes MG, Inc. 24
ArQule, Inc. 25
Bayer AG 26
Biogen, Inc. 27
Bionomics Limited 28
Biotecnol, Inc. 29
Boehringer Ingelheim GmbH 30
Boston Biomedical, Inc. 31
Bristol-Myers Squibb Company 32
CanBas Co., Ltd. 33
Concordia Healthcare Corp. 34
Eli Lilly and Company 35
EnGeneIC Ltd 36
F. Hoffmann-La Roche Ltd. 37
Five Prime Therapeutics, Inc. 38
Genelux Corporation 39
GlaxoSmithKline Plc 40
Juno Therapeutics Inc. 41
Merck & Co., Inc. 42
Millennium Pharmaceuticals, Inc. 43
MolMed S.p.A. 44
Morphotek, Inc. 45
Novartis AG 46
Ono Pharmaceutical Co., Ltd. 47
Oxford BioMedica Plc 48
Pfizer Inc. 49
Pharma Mar, S.A. 50
Polaris Pharmaceuticals, Inc. 51
Sellas Inc. 52
Synta Pharmaceuticals Corp. 53
VasGene Therapeutics, Inc. 54
Verastem, Inc. 55
Virttu Biologics Limited 56
Vyriad 57
Malignant Pleural Mesothelioma - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Target 59
Assessment by Mechanism of Action 62
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
Ad5-SGE-REIC/Dkk3 - Drug Profile 69
alisertib - Drug Profile 71
amatuximab - Drug Profile 76
anetumab ravtansine - Drug Profile 79
ascrinvacumab - Drug Profile 81
bevacizumab - Drug Profile 82
BG-00001 - Drug Profile 89
BMS-986148 - Drug Profile 90
BNC-105 - Drug Profile 91
CBP-501 - Drug Profile 94
Cellular Immunotherapy for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile 96
Cellular Immunotherapy for Oncology and Infectious Disease - Drug Profile 97
CRS-207 - Drug Profile 98
CSG-MESO - Drug Profile 101
defactinib hydrochloride - Drug Profile 102
FP-1039 - Drug Profile 104
galinpepimut-S - Drug Profile 106
ganetespib - Drug Profile 108
GEN-0101 - Drug Profile 113
Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile 115
Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile 116
GLONC-1 - Drug Profile 117
GSK-2256098 - Drug Profile 120
HSV-1716 - Drug Profile 122
iCasp9M28z - Drug Profile 125
JTCR-016 - Drug Profile 126
LY-3023414 - Drug Profile 127
MesoCancerVac - Drug Profile 129
MesoCART - Drug Profile 130
Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile 131
napabucasin - Drug Profile 133
NGR-hTNF - Drug Profile 136
nintedanib - Drug Profile 140
nivolumab - Drug Profile 145
Oncolytic Virus to Target CD46 for Malignant Pleural Mesothelioma - Drug Profile 153
OXB-301 - Drug Profile 154
pegargiminase - Drug Profile 157
pembrolizumab - Drug Profile 161
porfimer sodium - Drug Profile 172
rAd-IFN - Drug Profile 174
S-588210 - Drug Profile 176
Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile 177
TargomiRs - Drug Profile 178
Tb-535 - Drug Profile 180
tivantinib - Drug Profile 181
trabectedin - Drug Profile 184
Vas-01 - Drug Profile 190
VS-5584 - Drug Profile 192
Malignant Pleural Mesothelioma - Recent Pipeline Updates 194
Malignant Pleural Mesothelioma - Dormant Projects 302
Malignant Pleural Mesothelioma - Discontinued Products 303
Malignant Pleural Mesothelioma - Product Development Milestones 304
Featured News & Press Releases 304
Appendix 314
Methodology 314
Coverage 314
Secondary Research 314
Primary Research 314
Expert Panel Validation 314
Contact Us 314
Disclaimer 315
List of Tables
Number of Products under Development for Malignant Pleural Mesothelioma, H1 2016 13
Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Development, H1 2016 20
Products under Development by Companies, H1 2016 21
Products under Development by Companies, H1 2016 (Contd..1) 22
Products under Development by Companies, H1 2016 (Contd..2) 23
Products under Investigation by Universities/Institutes, H1 2016 24
Malignant Pleural Mesothelioma - Pipeline by Aduro BioTech, Inc., H1 2016 25
Malignant Pleural Mesothelioma - Pipeline by Advantagene, Inc., H1 2016 26
Malignant Pleural Mesothelioma - Pipeline by Amphera BV, H1 2016 27
Malignant Pleural Mesothelioma - Pipeline by AnGes MG, Inc., H1 2016 28
Malignant Pleural Mesothelioma - Pipeline by ArQule, Inc., H1 2016 29
Malignant Pleural Mesothelioma - Pipeline by Bayer AG, H1 2016 30
Malignant Pleural Mesothelioma - Pipeline by Biogen, Inc., H1 2016 31
Malignant Pleural Mesothelioma - Pipeline by Bionomics Limited, H1 2016 32
Malignant Pleural Mesothelioma - Pipeline by Biotecnol, Inc., H1 2016 33
Malignant Pleural Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 34
Malignant Pleural Mesothelioma - Pipeline by Boston Biomedical, Inc., H1 2016 35
Malignant Pleural Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H1 2016 36
Malignant Pleural Mesothelioma - Pipeline by CanBas Co., Ltd., H1 2016 37
Malignant Pleural Mesothelioma - Pipeline by Concordia Healthcare Corp., H1 2016 38
Malignant Pleural Mesothelioma - Pipeline by Eli Lilly and Company, H1 2016 39
Malignant Pleural Mesothelioma - Pipeline by EnGeneIC Ltd, H1 2016 40
Malignant Pleural Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 41
Malignant Pleural Mesothelioma - Pipeline by Five Prime Therapeutics, Inc., H1 2016 42
Malignant Pleural Mesothelioma - Pipeline by Genelux Corporation, H1 2016 43
Malignant Pleural Mesothelioma - Pipeline by GlaxoSmithKline Plc, H1 2016 44
Malignant Pleural Mesothelioma - Pipeline by Juno Therapeutics Inc., H1 2016 45
Malignant Pleural Mesothelioma - Pipeline by Merck & Co., Inc., H1 2016 46
Malignant Pleural Mesothelioma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 47
Malignant Pleural Mesothelioma - Pipeline by MolMed S.p.A., H1 2016 48
Malignant Pleural Mesothelioma - Pipeline by Morphotek, Inc., H1 2016 49
Malignant Pleural Mesothelioma - Pipeline by Novartis AG, H1 2016 50
Malignant Pleural Mesothelioma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 51
Malignant Pleural Mesothelioma - Pipeline by Oxford BioMedica Plc, H1 2016 52
Malignant Pleural Mesothelioma - Pipeline by Pfizer Inc., H1 2016 53
Malignant Pleural Mesothelioma - Pipeline by Pharma Mar, S.A., H1 2016 54
Malignant Pleural Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 55
Malignant Pleural Mesothelioma - Pipeline by Sellas Inc., H1 2016 56
Malignant Pleural Mesothelioma - Pipeline by Synta Pharmaceuticals Corp., H1 2016 57
Malignant Pleural Mesothelioma - Pipeline by VasGene Therapeutics, Inc., H1 2016 58
Malignant Pleural Mesothelioma - Pipeline by Verastem, Inc., H1 2016 59
Malignant Pleural Mesothelioma - Pipeline by Virttu Biologics Limited, H1 2016 60
Malignant Pleural Mesothelioma - Pipeline by Vyriad, H1 2016 61
Assessment by Monotherapy Products, H1 2016 62
Number of Products by Stage and Target, H1 2016 64
Number of Products by Stage and Mechanism of Action, H1 2016 67
Number of Products by Stage and Route of Administration, H1 2016 70
Number of Products by Stage and Molecule Type, H1 2016 72
Malignant Pleural Mesothelioma Therapeutics - Recent Pipeline Updates, H1 2016 198
Malignant Pleural Mesothelioma - Dormant Projects, H1 2016 306
Malignant Pleural Mesothelioma - Discontinued Products, H1 2016 307
List of Figures
Number of Products under Development for Malignant Pleural Mesothelioma, H1 2016 13
Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Products, H1 2016 20
Assessment by Monotherapy Products, H1 2016 62
Number of Products by Top 10 Targets, H1 2016 63
Number of Products by Stage and Top 10 Targets, H1 2016 63
Number of Products by Top 10 Mechanism of Actions, H1 2016 66
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 66
Number of Products by Top 10 Routes of Administration, H1 2016 69
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 69
Number of Products by Top 10 Molecule Types, H1 2016 71
Number of Products by Stage and Top 10 Molecule Types, H1 2016 71
